Cognitive
VIP
Immunity
3
Amino acids
Molecular weight
Peptide
Type
Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide belonging to the glucagon/secretin superfamily. It is produced in many tissues including the gut, pancreas, and brain. VIP has potent vasodilatory, anti-inflammatory, and immunomodulatory effects. It binds to VPAC1 and VPAC2 receptors, triggering cAMP-mediated signaling cascades. Research shows therapeutic potential for pulmonary hypertension, diabetes, neurological disorders, and autoimmune conditions.
VIP binds to VPAC1 and VPAC2 G protein-coupled receptors, activating adenylyl cyclase and increasing intracellular cAMP and PKA activity. This triggers phosphorylation of CREB and other transcription factors. VIP causes vasodilation through NO-dependent and independent mechanisms, stimulates intestinal secretion, relaxes smooth muscle, inhibits gastric acid secretion, and has positive inotropic/chronotropic cardiac effects.
Lyophilized powder: 2-8°C refrigerated; Reconstituted: use immediately (very short stability, ~2 minute half-life)
1-2 times daily due to very short 2-minute half-life
50-100 mcg per dose (up to 200 mcg in research protocols)
As prescribed for specific condition
Potent vasodilation and blood pressure reduction
Strong anti-inflammatory effects
Immunomodulation (Th1-Th2 balance)
Neuroprotective effects
Bronchodilation
Cardioprotective (positive inotropic effects)
Insulin secretion enhancement (glucose-dependent)
Gut barrier and permeability regulation
This peptide is still gaining traction in the community.
Vasoactive Intestinal Peptide | Neuropeptide
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesView the scientifc details of VIP.
3
Amino Acids
VIP
His
His
Position 1
Trp
Trp
Position 2
Arg
Arg
Position 3
VIP has a very short half-life of approximately 2 minutes in blood, requiring careful dosing strategies. Subcutaneous or intravenous administration. Rapid degradation limits bioavailability; analogs like stearyl-Nle17-VIP (SNV) are 100-fold more potent.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| General use | 50 | 1 week range | SubQ or IV |
| Research protocols | 100 | — | SubQ or IV |
Materials needed:
Steps to reconstitute
The VIP Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
Dosing tools
Calculate peptide doses with our visual syringe guide.
0.3mL / 30 units
5 units
0.050 mL
1 mL
2 mL
3 mL
5 mL
Custom
Conversion: 1,000 mcg = 1 mg
Based on your vial and dilution inputs.
Safe concentration range
VIP
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg VIP vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
Research Purposes Only
These calculators are provided for educational and research purposes only. Always verify calculations and consult with qualified professionals. The information provided is not medical advice. Peptides should only be used in accordance with applicable laws and regulations.
Note: Triple agonist; microdose for fewer side effects
Research suggestions of VIP interactions with other common peptides and substances.
Severe hypotension
VIPoma or related tumors
Pregnancy or breastfeeding
Severe cardiac conditions
Severe hypotension
Allergic reaction symptoms
Severe diarrhea
Cardiac arrhythmias
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Peptides can support cellular repair, immune function, metabolic health, and tissue regeneration. Research suggests they may help with recovery, sleep quality, skin health, and cognitive function, depending on the specific peptide and its mechanism of action.
Current research explores peptides for longevity, muscle recovery, wound healing, metabolic disorders, and neuroprotection. Scientists are also investigating peptide-based drug delivery and targeted therapies that could offer more precise treatment options.
Peptides work by binding to receptors on cells and triggering specific biological responses. Depending on the peptide, they may promote growth hormone release, support collagen production, modulate inflammation, or influence neurotransmitter activity—each with different implications for health and wellness.
Peer-reviewed journals such as Nature, Science, and specialized publications like Peptides and the Journal of Peptide Science publish ongoing research. PubMed and Google Scholar are useful for searching studies by peptide name or condition.
Research use of peptides typically follows institutional review board (IRB) protocols and regulatory guidelines. Dosage, administration route, and safety monitoring should align with published literature and applicable regulations in your jurisdiction.
Peptides are short chains of amino acids (typically under 50), while proteins are longer chains that fold into complex structures. Peptides are often more stable, easier to synthesize, and can cross cell membranes more readily, making them attractive for therapeutic applications.
Most peptides require refrigeration (2–8°C) and protection from light. Reconstituted peptides often have shorter stability and may need to be used within days or weeks. Always follow the manufacturer's or research protocol's storage instructions.
Some peptides are bioavailable orally, but many are broken down by digestive enzymes before reaching the bloodstream. Subcutaneous injection, nasal administration, or other routes are often used in research to improve bioavailability. The optimal route depends on the specific peptide.
VIP is an extensively studied compound
VIP
VIP is an extensively studied compound
VIP as New Drug for Treatment of Primary Pulmonary Hypertension
VIP inhalation showed striking efficacy with increased mixed venous oxygen saturation and exercise capacity.
n.d.
Therapeutic Potential of VIP and VPAC2 in Type 2 Diabetes
VIP promotes glucose-dependent insulin secretion via VPAC2, reducing hypoglycemia risk.
n.d.
Therapeutic Potential of VIP in Neurological Disorders
VIP and receptors are promising therapeutic targets for AD, PD, and autism spectrum disorders.
n.d.
VIP Structure and Function for Therapeutic Applications
Comprehensive review of VIP receptor signaling and therapeutic applications.
n.d.